Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetylcysteine in Mitochondrial Disease with m.3243A>G Mutation
NCT05241262Phase 1Recruiting
- Start
- Jul 2023
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of acetylcysteine in mitochondrial disease. Primary endpoint: Maximum tolerated dose of NAC at 4 months. Started Jul 2023; status: recruiting.
02
Drugs
acetylcysteine
03
Conditions
mitochondrial disease
Beyond the preview
Go deeper on NCT05241262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05241262.